---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-25-000042"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T18:51:40.215863+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexicon Q2 net income of $3.3M vs loss; licensing revenue from Novo Nordisk drives top line

## Summary
- Total revenues $28.9M (vs $1.6M Q2'24) driven by $27.5M licensing from Novo Nordisk LX9851 deal.
- Net income $3.3M ($0.01 diluted EPS) vs net loss $53.4M ($0.17 loss) in Q2'24.
- SG&A expenses fell to $9.4M from $39.2M due to strategic repositioning and reduced INPEFA marketing.
- Cash & investments $139M at June 30, 2025, down from $238M at Dec 31, 2024, reflecting severance payments.
- Pipeline: pilavapadin partnership talks ongoing; LX9851 IND-enabling on track; SONATA enrollment target for 2026.

## SEC filing metadata
- accession: 0001062822-25-000042
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282225000042/0001062822-25-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282225000042/lxrx-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-25-000042
- JSON: https://secwatch.observer/filing/0001062822-25-000042.json
- Plain text: https://secwatch.observer/filing/0001062822-25-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.